NKTX Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -- compared to Nkarta, Inc.'s net margin of 19%. Nkarta, Inc.'s return on equity of -26.82% beat Biogen, Inc.'s return on equity of 9.36%.

Nkarta, Inc. has a consensus price target of $11.25, signalling upside risk potential of 525%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.4%. Given that Nkarta, Inc. has higher upside potential than Biogen, Inc., analysts believe Nkarta, Inc. is more attractive than Biogen, Inc..

Nkarta, Inc. has a beta of 0.799, which suggesting that the stock is 20.142% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Nkarta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nkarta, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Nkarta, Inc. quarterly revenues are --, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Nkarta, Inc.'s net income of -$21.7M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Nkarta, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nkarta, Inc. is -- versus 2.74x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Nkarta, Inc.'s net margin of --. Nkarta, Inc.'s return on equity of -26.82% beat CEL-SCI Corp.'s return on equity of -266.61%.

Nkarta, Inc. has a consensus price target of $11.25, signalling upside risk potential of 525%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Nkarta, Inc., analysts believe CEL-SCI Corp. is more attractive than Nkarta, Inc..

Nkarta, Inc. has a beta of 0.799, which suggesting that the stock is 20.142% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Nkarta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nkarta, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Nkarta, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Nkarta, Inc.'s net income of -$21.7M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Nkarta, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nkarta, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Nkarta, Inc.'s net margin of -953.4%. Nkarta, Inc.'s return on equity of -26.82% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Nkarta, Inc. has a consensus price target of $11.25, signalling upside risk potential of 525%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Nkarta, Inc., analysts believe IGC Pharma, Inc. is more attractive than Nkarta, Inc..

Nkarta, Inc. has a beta of 0.799, which suggesting that the stock is 20.142% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Nkarta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nkarta, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Nkarta, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Nkarta, Inc.'s net income of -$21.7M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Nkarta, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nkarta, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Nkarta, Inc.'s net margin of -255.85%. Nkarta, Inc.'s return on equity of -26.82% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Nkarta, Inc. has a consensus price target of $11.25, signalling upside risk potential of 525%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Nkarta, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Nkarta, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Nkarta, Inc. has a beta of 0.799, which suggesting that the stock is 20.142% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Nkarta, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Nkarta, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nkarta, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Nkarta, Inc.'s net income of -$21.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Nkarta, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nkarta, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.